NCIt definition : A cancer vaccine containing four HLA-A*0201-restricted peptide epitopes with potential
immunostimulatory and antitumor activities. Vaccine peptide epitopes are derived from
the tumor associated antigens (TAAs) tyrosinase-related protein 2 (TRP2), glycoprotein
100 (gp100), Ephrin receptor A2 (EphA2) and human epidermal growth factor receptor
2 (HER2). Upon administration, HLA-A*0201-restricted TRp2-gp100-EphA2-HER2 multipeptide
vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against TRP2-gp100-EphA2-HER2-expressing
tumor cells, resulting in tumor cell lysis and decreased tumor cell proliferation.
HLA-A*0201 is an MHC class I molecule that presents antigenic peptides to CD8 T cells;
epitope design restricted to epitopes that bind most efficiently to HLA-A*0201 may
improve antigenic peptide immunogenicity.;